1.Analysis of the current state of obesity research in China over the past decade from 2014 to 2023 based on National Natural Science Foundation funding
Wen XIAO ; Jiali FANG ; Zhenggang WU ; Xianwei CUI
Chinese Journal of Endocrinology and Metabolism 2025;41(10):855-860
Objective:To review and analyze obesity-related research projects funded by the National Natural Science Foundation of China(NSFC) to understand the overall landscape and hotspots of approval in this field, and to provide reference for subsequent applicants.Methods:To assess the funding situation of obesity-related projects from 2014 to 2023, we used " obesity" as a search term to extract project information from ZCOOL, LetPub, and MedSci databases. The data were organized, frequency statistics were performed, and results were presented visually using Excel spreadsheets.Results:Over the past 10 years, the NSFC has funded a total of 778 obesity-related research projects with a funding amount of 350 million yuan, showing a constant upward trend. In terms of project types, general projects and youth projects accounted for 87.66%, with other categories, such as key projects, regional projects, major research plans, and international collaboration projects, providing diversified support for obesity research. In terms of disciplinary distribution, obesity-related projects encompass not only medical and life sciences but also fields such as chemistry, information science, earth science, mathematical sciences, management, and others, demonstrating the interdisciplinary integration of research. The primary research directions include obesity prevention and treatment and obesity-related complications. Regional analysis indicates that the issue of uneven development among provinces persists in obesity research.Conclusion:The continuous investment of NSFC in obesity-related research has contributed to the advancement of obesity research in China, enabling the country to play a leading role in the international field.
2.Analysis of the current state of obesity research in China over the past decade from 2014 to 2023 based on National Natural Science Foundation funding
Wen XIAO ; Jiali FANG ; Zhenggang WU ; Xianwei CUI
Chinese Journal of Endocrinology and Metabolism 2025;41(10):855-860
Objective:To review and analyze obesity-related research projects funded by the National Natural Science Foundation of China(NSFC) to understand the overall landscape and hotspots of approval in this field, and to provide reference for subsequent applicants.Methods:To assess the funding situation of obesity-related projects from 2014 to 2023, we used " obesity" as a search term to extract project information from ZCOOL, LetPub, and MedSci databases. The data were organized, frequency statistics were performed, and results were presented visually using Excel spreadsheets.Results:Over the past 10 years, the NSFC has funded a total of 778 obesity-related research projects with a funding amount of 350 million yuan, showing a constant upward trend. In terms of project types, general projects and youth projects accounted for 87.66%, with other categories, such as key projects, regional projects, major research plans, and international collaboration projects, providing diversified support for obesity research. In terms of disciplinary distribution, obesity-related projects encompass not only medical and life sciences but also fields such as chemistry, information science, earth science, mathematical sciences, management, and others, demonstrating the interdisciplinary integration of research. The primary research directions include obesity prevention and treatment and obesity-related complications. Regional analysis indicates that the issue of uneven development among provinces persists in obesity research.Conclusion:The continuous investment of NSFC in obesity-related research has contributed to the advancement of obesity research in China, enabling the country to play a leading role in the international field.
3.Efficacy of autologous platelet-rich plasma in the treatment of acute injury to the anterior talofibular ligament
Liang LIU ; Congcong ZENG ; Yan XIAO ; Zhenggang WANG ; Lei XIANG ; Hongbing JIANG ; Cheng LIU ; Shengyao LIU ; Liangxing XIAO ; Wei LIU
Chinese Journal of Orthopaedic Trauma 2025;27(7):634-639
Objective:To explore the clinical efficacy of autologous platelet-rich plasma (PRP) in the treatment of acute injury to the anterior talofibular ligament (ATFL).Methods:A retrospective study was conducted to analyze the data of 96 patients who had been admitted to Department of Orthopedic Trauma Repair, The Nanhua Hospital Affiliated to Hengyang Medical School for acute ATFL injuries of grades Ⅰ & Ⅱ from January 2022 to December 2023. They were divided into 2 groups according to their different treatments. In the PRP group subjected to local PRP injection combined with conservative treatment, there were 49 patients (28 males and 21 females), with an age of (32.5±6.5) years. In the conservative group subjected to traditional conservative treatment, there were 47 patients (24 males and 23 females), with an age of (30.5±5.3) years. The 2 groups were compared in terms of visual analog scale (VAS) pain scores, talar anterior translations, Karlsson scores, American Orthopaedic Foot & Ankle Society (AOFAS) ankle-hindfoot scores before and 6 months after treatment.Results:No statistically significant differences were observed in the baseline characteristics between the 2 groups before treatment, indicating comparability ( P>0.05). All patients were followed up for (9.1±1.7) months. In both groups, the VAS pain scores significantly decreased after treatment than the pre-treatment ones, the talar anterior translations significantly reduced after treatment than the pre-treatment ones, and the AOFAS and Karlsson scores significantly increased after treatment than the pre-treatment ones ( P < 0.05). After 6 months of treatment, the talar translation distance [(2.5±0.4) mm], AOFAS ankle hind foot score [(91.7 ± 4.0) points], and Karlsson score [(93.0±3.5) points] in the PRP group were significantly better than those in the conservative group [(6.1±0.9) mm, (87.1±4.3) points, (89.0±4.0) points]( P < 0.05). Conclusion:In the treatment of acute ATFL injury, PRP therapy demonstrates good clinical efficacy, for it can significantly reduce pain, promote functional recovery, and improve joint stability.
4.Efficacy and safety of BTX-A in alleviating postoperative pain and reducing capsular contracture after breast augmentation surgery
Chong JING ; Xiaopeng WANG ; Zhenggang XIAO
Chinese Journal of Medical Aesthetics and Cosmetology 2025;31(2):167-171
Objective:To explore the efficacy and safety of type A botulinum toxin (BTX-A) in alleviating pain and reducing capsular contracture after breast augmentation surgery.Methods:This single-center, double-blind, and randomized controlled trial included 212 female patients who underwent breast augmentation surgery at Changsha YaMei Medical Cosmetic Hospital from May 2020 to January 2021. Patients were divided into two groups according to whether BTX-A was injected into the pectoralis major during the augmentation: 106 in the BTX-A group, with an average age of (33.1±3.8) years; and 106 in the control group, with an average age of (33.3±3.5) years. The visual analogue scale (VAS) was used to assess pain on days 1, 3 and 7 post-operation. After two years of follow-up, the postoperative VAS scores, duration of pain, rates of capsular contracture, and incidence of adverse reactions were compared between the two groups.Results:One case was lost to follow-up in each group. On postoperative days 1 and 3, the VAS scores of the BTX-A group were (3.93±1.77) and (5.35±2.04) scores, respectively, lower than those of the control group, which were (5.93±2.17) and (7.34±1.75) scores (both P<0.001). On day 7, the scores were (1.96±1.71) and (2.26±1.90) scores, respectively, with no statistically significant difference ( P=0.225). The pain severity in both groups showed a trend of initial increase followed by a decrease, with a significant difference ( P<0.001). The duration of pain in the BTX-A group was (2.6±1.8) days, shorter than that in the control group (4.9±2.1) days, with a statistically significant difference ( P<0.001). The rate of capsular contracture in the BTX-A group was 0.95% (1/105), compared to 1.90% (2/105) in the control group, with no statistically significant difference ( P=1.000). The incidence of adverse reactions was 11.32% (12/106) in the BTX-A group and 10.38% (11/106) in the control group, with no statistically significant difference ( P=0.825). There were no severe adverse reactions such as respiratory or cardiovascular events or deaths in either group. Conclusion:BTX-A can alleviate pain after breast augmentation surgery with high safety. However, it does not have a significant advantage in preventing capsular contracture.
5.Changpu Yujin Tang alleviates neuroinflammation in rats with Tourette syndrome by inhibiting the NLRP3/Caspase-1/GSDMD signaling pathway
Shuang HUANG ; Mengxue LI ; Liwei HUANG ; Mingyang SUN ; Kexin SUN ; Xing WEI ; Xiao LIU ; Huan LYU ; Zhenggang SHI
Immunological Journal 2025;41(4):231-236
Objective To explore the effects and mechanisms of Changpu Yujin Tang(CPYJT)on the NOD-like receptor thermal protein domain associated protein 3/cysteinyl aspartate specific proteinase-1/Gasdermin D(NLRP3/Caspase-1/GSDMD)signaling pathway-mediated neuroinflammation in rats with Tourette syndrome(TS).Methods SPF-grade male SD rats were randomly divided into the Control and TS groups.After successful modeling in the TS group,the rats were randomly divided into the Model,Tiapride,and CPYJT groups,and were treated with the corresponding drugs for 4 weeks.After the treatment,the rats' behavior was scored,H & E staining was used to observe pathological changes in the striatum,ELISA was used to measure the content of IL-1β and IL-18,RT-qPCR was used to detect the expression of NLRP3 and ASC mRNA,and Western blot was used to detect the expression of NLRP3,ASC,Caspase-1,Cleaved-Caspase-1,GSDMD,and GSDMD-NT proteins.Results Compared with the Control group,the Model group showed increased scores of stereotyped and motor behaviors(P<0.01),pathological changes in the striatal tissue,increased content of IL-1β and IL-18(P<0.01),and upregulated expression of NLRP3,ASC mRNA,and NLRP3,ASC,Caspase-1,Cleaved-Caspase-1,GSDMD,and GSDMD-NT proteins(P<0.01).Compared with the Model group,the Tiapride group and the CPYJT group showed decreased scores of stereotyped and motor behaviors(P<0.01),improved pathological damage in the striatal tissue,reduced content of IL-1β and IL-18(P<0.01),and inhibited expression of NLRP3,ASC mRNA,and NLRP3,ASC,Caspase-1,Cleaved-Caspase-1,GSDMD,and GSDMD-NT proteins(P<0.01).Conclusion The therapeutic effect of CPYJT on TS is related to the inhibition of the neuroinflammatory response mediated by the NLRP3/Caspase-1/GSDMD signaling pathway.
6.Changpu Yujin Tang alleviates neuroinflammation in rats with Tourette syndrome by inhibiting the NLRP3/Caspase-1/GSDMD signaling pathway
Shuang HUANG ; Mengxue LI ; Liwei HUANG ; Mingyang SUN ; Kexin SUN ; Xing WEI ; Xiao LIU ; Huan LYU ; Zhenggang SHI
Immunological Journal 2025;41(4):231-236
Objective To explore the effects and mechanisms of Changpu Yujin Tang(CPYJT)on the NOD-like receptor thermal protein domain associated protein 3/cysteinyl aspartate specific proteinase-1/Gasdermin D(NLRP3/Caspase-1/GSDMD)signaling pathway-mediated neuroinflammation in rats with Tourette syndrome(TS).Methods SPF-grade male SD rats were randomly divided into the Control and TS groups.After successful modeling in the TS group,the rats were randomly divided into the Model,Tiapride,and CPYJT groups,and were treated with the corresponding drugs for 4 weeks.After the treatment,the rats' behavior was scored,H & E staining was used to observe pathological changes in the striatum,ELISA was used to measure the content of IL-1β and IL-18,RT-qPCR was used to detect the expression of NLRP3 and ASC mRNA,and Western blot was used to detect the expression of NLRP3,ASC,Caspase-1,Cleaved-Caspase-1,GSDMD,and GSDMD-NT proteins.Results Compared with the Control group,the Model group showed increased scores of stereotyped and motor behaviors(P<0.01),pathological changes in the striatal tissue,increased content of IL-1β and IL-18(P<0.01),and upregulated expression of NLRP3,ASC mRNA,and NLRP3,ASC,Caspase-1,Cleaved-Caspase-1,GSDMD,and GSDMD-NT proteins(P<0.01).Compared with the Model group,the Tiapride group and the CPYJT group showed decreased scores of stereotyped and motor behaviors(P<0.01),improved pathological damage in the striatal tissue,reduced content of IL-1β and IL-18(P<0.01),and inhibited expression of NLRP3,ASC mRNA,and NLRP3,ASC,Caspase-1,Cleaved-Caspase-1,GSDMD,and GSDMD-NT proteins(P<0.01).Conclusion The therapeutic effect of CPYJT on TS is related to the inhibition of the neuroinflammatory response mediated by the NLRP3/Caspase-1/GSDMD signaling pathway.
7.Efficacy of autologous platelet-rich plasma in the treatment of acute injury to the anterior talofibular ligament
Liang LIU ; Congcong ZENG ; Yan XIAO ; Zhenggang WANG ; Lei XIANG ; Hongbing JIANG ; Cheng LIU ; Shengyao LIU ; Liangxing XIAO ; Wei LIU
Chinese Journal of Orthopaedic Trauma 2025;27(7):634-639
Objective:To explore the clinical efficacy of autologous platelet-rich plasma (PRP) in the treatment of acute injury to the anterior talofibular ligament (ATFL).Methods:A retrospective study was conducted to analyze the data of 96 patients who had been admitted to Department of Orthopedic Trauma Repair, The Nanhua Hospital Affiliated to Hengyang Medical School for acute ATFL injuries of grades Ⅰ & Ⅱ from January 2022 to December 2023. They were divided into 2 groups according to their different treatments. In the PRP group subjected to local PRP injection combined with conservative treatment, there were 49 patients (28 males and 21 females), with an age of (32.5±6.5) years. In the conservative group subjected to traditional conservative treatment, there were 47 patients (24 males and 23 females), with an age of (30.5±5.3) years. The 2 groups were compared in terms of visual analog scale (VAS) pain scores, talar anterior translations, Karlsson scores, American Orthopaedic Foot & Ankle Society (AOFAS) ankle-hindfoot scores before and 6 months after treatment.Results:No statistically significant differences were observed in the baseline characteristics between the 2 groups before treatment, indicating comparability ( P>0.05). All patients were followed up for (9.1±1.7) months. In both groups, the VAS pain scores significantly decreased after treatment than the pre-treatment ones, the talar anterior translations significantly reduced after treatment than the pre-treatment ones, and the AOFAS and Karlsson scores significantly increased after treatment than the pre-treatment ones ( P < 0.05). After 6 months of treatment, the talar translation distance [(2.5±0.4) mm], AOFAS ankle hind foot score [(91.7 ± 4.0) points], and Karlsson score [(93.0±3.5) points] in the PRP group were significantly better than those in the conservative group [(6.1±0.9) mm, (87.1±4.3) points, (89.0±4.0) points]( P < 0.05). Conclusion:In the treatment of acute ATFL injury, PRP therapy demonstrates good clinical efficacy, for it can significantly reduce pain, promote functional recovery, and improve joint stability.
8.Efficacy and safety of BTX-A in alleviating postoperative pain and reducing capsular contracture after breast augmentation surgery
Chong JING ; Xiaopeng WANG ; Zhenggang XIAO
Chinese Journal of Medical Aesthetics and Cosmetology 2025;31(2):167-171
Objective:To explore the efficacy and safety of type A botulinum toxin (BTX-A) in alleviating pain and reducing capsular contracture after breast augmentation surgery.Methods:This single-center, double-blind, and randomized controlled trial included 212 female patients who underwent breast augmentation surgery at Changsha YaMei Medical Cosmetic Hospital from May 2020 to January 2021. Patients were divided into two groups according to whether BTX-A was injected into the pectoralis major during the augmentation: 106 in the BTX-A group, with an average age of (33.1±3.8) years; and 106 in the control group, with an average age of (33.3±3.5) years. The visual analogue scale (VAS) was used to assess pain on days 1, 3 and 7 post-operation. After two years of follow-up, the postoperative VAS scores, duration of pain, rates of capsular contracture, and incidence of adverse reactions were compared between the two groups.Results:One case was lost to follow-up in each group. On postoperative days 1 and 3, the VAS scores of the BTX-A group were (3.93±1.77) and (5.35±2.04) scores, respectively, lower than those of the control group, which were (5.93±2.17) and (7.34±1.75) scores (both P<0.001). On day 7, the scores were (1.96±1.71) and (2.26±1.90) scores, respectively, with no statistically significant difference ( P=0.225). The pain severity in both groups showed a trend of initial increase followed by a decrease, with a significant difference ( P<0.001). The duration of pain in the BTX-A group was (2.6±1.8) days, shorter than that in the control group (4.9±2.1) days, with a statistically significant difference ( P<0.001). The rate of capsular contracture in the BTX-A group was 0.95% (1/105), compared to 1.90% (2/105) in the control group, with no statistically significant difference ( P=1.000). The incidence of adverse reactions was 11.32% (12/106) in the BTX-A group and 10.38% (11/106) in the control group, with no statistically significant difference ( P=0.825). There were no severe adverse reactions such as respiratory or cardiovascular events or deaths in either group. Conclusion:BTX-A can alleviate pain after breast augmentation surgery with high safety. However, it does not have a significant advantage in preventing capsular contracture.
9.Data Mining Study on the Prescription Law of TCM for the Treatment of Epilepsy Based on National Patent Database
Rong LIN ; Lü GAO ; Yanan XIAO ; Shuang HUANG ; Jing SHANG ; Zhenggang SHI
Chinese Journal of Information on Traditional Chinese Medicine 2024;31(7):44-49
Objective To explore the prescription law of Chinese materia medica for the treatment of epilepsy based on National Patent Database;To provide references for clinical treatment.Methods Patent data on TCM compounds for treating epilepsy that met the inclusion criteria were collected from the establishment of the Chinese Patent Publication Announcement Network until August 21,2023.Excel 2021 was used to establish the database of prescription medication.Python,SPSS Modeler 18.0,Cytoscape 3.10.1,and R language software were used to model prescription data,analyze medication frequency,conduct complex network analysis,association rule analysis,clustering analysis,to explore the prescription law.Results A total of 376 patents meeting the criteria for epilepsy were included,involving 827 kinds of Chinese materia medica,with a total frequency of 4 911 times.Gastrodiae Rhizoma,Acori Tatarinowii Rhizoma,Bombyx Batryticatus,Scorpio,Uncariae Ramulus cum Uncis were among the top five frequently used Chinese materia medica.The high-frequency drug efficacy categories were primarily liver soothing and wind alleviating drugs,tranquilizers,and phlegm resolving,cough suppressing,and asthma alleviating drugs.The predominant medicinal properties were mild,warm and cold,while the predominant tastes were sweet,pungent and bitter.The herbs were classified under the liver,heart,lung and spleen meridians.The core complex network of Chinese materia medica was identified,and the core combination was Gastrodiae Rhizoma-Acori Tatarinowii Rhizoma-Bombyx Batryticatus.The association rule analysis identified 28 commonly used medicinal combinations,with the highest support being observed for Scorpio-Bombyx Batryticatus.Clustering analysis yields four sets of data.Similarity analysis revealed the unique properties of the patented compound in the treatment of epilepsy.Conclusion The high-frequency drugs and commonly used drug combinations of TCM compounds for treating epilepsy,as disclosed on the Chinese Patent Publication Announcement Network,are primarily aimed at calming wind and stopping convulsions,as well as resolving phlegm and opening the orifices,which can provide reference for clinical practice.
10.Effects of ICMT gene silencing on the invasion and migration of human salivary adenoid cystic carcinoma cells in vitro
LU Zhou ; GONG Wenhong ; XU Xiao ; CHEN Zhenggang
Journal of Prevention and Treatment for Stomatological Diseases 2023;31(6):400-407
Objective :
To investigate the effect of isoprene cysteine carboxymethyltransferase (ICMT) gene on the migration and invasion of salivary adenoid cystic cancer cells (SACC) and the related mechanism, to provide experimental evidence for molecular targeted therapy of SACC.
Methods:
Adenoid cystic cancer cells SACC-LM and SACC-83 were cultured in vitro, and siRNA was transfected into human SACC-LM and SACC-83 cells (experimental group) by transient transfection of a liposome vector. A blank control group and negative control group were set up respectively (transfected NC-siRNA). qRT-PCR was peformed to measure the mRNA expression of ICMT and RhoA in each group after transfection and to determine the silencing efficiency. The expression of ICMT, membrane RhoA, total RhoA, matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and Rho associated with coiled helical binding protein kinase 1 (ROCK1) in each group was detected by Western blot. The proliferation abilityies of SACC cells was detected by CCK-8 assay. The migration and invasion ability of SACC cells were detected by comparing the relative healing area of cell scratch assay and the number of Transwell assay cells.
Results:
After transfection of ICMT-siRNA into SACC-LM and SACC-83 cells, the expression of ICMT gene and protein in the experimental group was significantly decreased compared with the negative control group and blank control group (P<0.05), but there were no significant differences in the expression of RhoA gene and total protein among all groups (P>0.05). The expression of RhoA membrane proteins, ROCK1, MMP-2, MMP-9 in the experimental group was significantly decreased compared with that in the negative control group and blank control group (P<0.05). Cell proliferation ability was significantly decreased (P<0.05). The migration and invasion abilities were significantly decreased (P<0.05).
Conclusion
In vitro silencing of ICMT gene can effectively inhibit the migration and invasion of human SACC-LM and SACC-83 cells, and the mechanism may be related to RhoA-ROCK signaling pathway.


Result Analysis
Print
Save
E-mail